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Abstract
Background: Artemisinin combination treatments (ACT) are recommended as first line treatment for falciparum malaria
throughout the malaria affected world. We reviewed the efficacy of a 3-day regimen of mefloquine and artesunate regimen
(MAS3), over a 13 year period of continuous deployment as first-line treatment in camps for displaced persons and in clinics
for migrant population along the Thai-Myanmar border.
Methods and Findings: 3,264 patients were enrolled in prospective treatment trials between 1995 and 2007 and treated
with MAS3. The proportion of patients with parasitaemia persisting on day-2 increased significantly from 4.5% before 2001
to 21.9% since 2002 (p,0.001). Delayed parasite clearance was associated with increased risk of developing
gametocytaemia (AOR= 2.29; 95% CI, 2.00–2.69, p= 0.002). Gametocytaemia on admission and carriage also increased
over the years (p= 0.001, test for trend, for both). MAS3 efficacy has declined slightly but significantly (Hazards ratio 1.13;
95% CI, 1.07–1.19, p,0.001), although efficacy in 2007 remained well within acceptable limits: 96.5% (95% CI, 91.0–98.7).
The in vitro susceptibility of P. falciparum to artesunate increased significantly until 2002, but thereafter declined to levels
close to those of 13 years ago (geometric mean in 2007: 4.2 nM/l; 95% CI, 3.2–5.5). The proportion of infections caused by
parasites with increased pfmdr1 copy number rose from 30% (12/40) in 1996 to 53% (24/45) in 2006 (p= 0.012, test for
trend).
Conclusion: Artesunate-mefloquine remains a highly efficacious antimalarial treatment in this area despite 13 years of
widespread intense deployment, but there is evidence of a modest increase in resistance. Of particular concern is the
slowing of parasitological response to artesunate and the associated increase in gametocyte carriage.
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Introduction
The Thai-Myanmar border harbors some of the world’s most
drug resistant malaria parasites. Plasmodium falciparum parasites in
this region have developed significant resistance to commonly used
antimalarials, except the artemisinin derivatives. The treatment of
uncomplicated P. falciparum malaria in Thailand has been modified
several times during the past 30 years to counter the rapid
emergence and spread of drug resistance [1,2]. A two-day
combination of mefloquine and artesunate, MAS2, (artesunate
6 mg/kg repeated once 24 hours later), was introduced in
Thailand in 1995, under strict supervision, exclusively in three
provinces (including the northwestern border of Thailand) where
failure rates with mefloquine (15 mg/kg) -sulfadoxine-pyrimeth-
amine (MSP) had risen above 50% [3]. In 2004,MAS2 was extended
to all provinces along the borders with Myanmar and Cambodia,
following evidence from these areas of inadequate clinical cure rates
with mefloquine alone, or MSP [4–6]. Use of both drugs has been
strictly controlled and neither mefloquine nor artesunate are
available in the private sector on the Thai side of the border.
In camps for displaced persons located along the Thai-
Myanmar border, mefloquine and artesunate combination
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therapy has been evaluated since 1991 and deployed systemati-
cally since 1994 [7,8]. The total dose of artesunate (12 mg/kg) was
the same as that in the National protocol, but the duration of the
treatment was 3 days (4 mg/kg/day) i.e. MAS3, to ensure that
artesunate covered two parasite asexual life-cycles, thereby
reducing the parasite biomass exposed to mefloquine alone [9].
MAS3, one of the ACT regimens currently recommended by the
WHO, is also used in clinics serving the migrant population,
located along the Thai-Myanmar border, and since January 2008
has replaced MAS2 in the Thailand National protocol.
This report presents a continuous description of the in vivo, in
vitro and molecular correlates of MAS3 efficacy in the thirteen
years between January 1995 and December 2007 in camps for
displaced people and clinics for migrant workers located along the
northwestern border of Thailand.
Methods
Study area
The epidemiology of malaria in the area has been described in
detail elsewhere [10]. Briefly, malaria is seasonal, the transmission
is low and unstable, P. falciparum and P. vivax are the two
predominant species, P. malariae is occasionally found, and P. ovale
is rare. All age groups are affected and nearly all the P. falciparum
infections are symptomatic. Since 1995, the Shoklo Malaria
Research Unit (SMRU) has conducted 7 prospective randomized
open-label controlled chemotherapeutic trials of new antimalarial
drugs in which MAS3 was one of the treatment arms [11–17] and
two non-comparative trials of MAS3 drug efficacy [18].
Assessment of treatment regimens
Three methodologies were use to evaluate MAS3 efficacy: in
vivo, in vitro and molecular assessment of pfmdr1 copy number.
The in vivo efficacy of MAS3 has been monitored annually
[18,19]. The prospective analysis of in vivo efficacy was restricted
to studies after 1994, when distinction of recrudescent from novel
infections was made possible by the introduction of PCR parasite
genotyping [20], thereby ensuring accurate assessment of
recrudescence rates. Post-treatment follow-up was extended to
42–63 days to minimize underestimation of true failure rates
[21,22].
In vitro antimalarial drug susceptibility studies were carried out
on fresh isolates of P. falciparum parasites from 1995 onwards [23].
Studies in this location have demonstrated that amplification of
pfmdr1 gene copy number is the major molecular determinant of
mefloquine susceptibility and provides an important tool for
monitoring drug resistance [24,25].
In vivo studies of drug efficacy
Study procedures. Specific study procedures have been
described previously for each randomized controlled trial [11–17];
most enrolment procedures were common to all studies. In brief
patients, who presented to the SMRU clinics (all located along
100 km of the Thai-Myanmar border) with a microscopically
confirmed uncomplicated P. falciparum malaria or a mixed
infection, were enrolled after giving written (all randomized trials
and all non-comparative trials since 1996) or witnessed verbal
consent (non-comparative trials conducted in 1995). Severely ill
patients and hyperparasitaemic patients (4% or more infected red
blood cells on a thin malaria smear) were treated with different
regimens and were not included in this analysis. Patients who had
received treatment with mefloquine in the previous 63 days or who
had failed their last antimalarial drug treatment, pregnant women,
children ,5 kg in body weight, and patients with signs of severity
or concomitant disease were excluded from the studies. All
patients were examined daily until fever subsided (fever being
defined as an axillary, rectal or tympanic temperature$37.5uC)
and until parasite clearance (defined as the absence of P. falciparum
trophozoites on the malaria smear), and then followed weekly for 6
to 9 weeks. In the event of parasite reappearance during follow up
patients were re-treated and followed-up again. The clinical trials
conducted at SMRU were all reviewed by the Ethics Committee
of the Faculty of Tropical Medicine Mahidol University and the
Oxford Tropical Research Ethics Committee.
Drug regimens. Patients received oral artesunate (Guilin
Pharmaceutical Factory, Guilin, Guangxi, People’s Republic of
China) or ArsumaxH (Sanofi-Aventis, Gentilly-France) 4 mg/kg/
day for 3 days once daily, and mefloquine 25 mg base/kg,
LariamH (Roche, Basel-Switzerland) or MequinH (Atlantic
Laboratories, Bangkok-Thailand). Children who were unable to
swallow complete tablets received the same weight-adjusted
dosage of crushed tablets mixed with water. Each drug
administration was observed in all patients.
Patients received mefloquine either as a single dose of 25 mg/kg
(during trials conducted before 1996), as a split dose of 15 mg/kg
and 10 mg/kg given 24 hrs apart on the second and third day of
treatment (the current protocol), or as a split dose of 8 mg/kg
given once a day for 3 days in two trials [15,16].
In the 2006 dose-assessment study [17], half of the patients
received a newly developed fixed co-formulation of mefloquine
HCl 220 mg (or mef 200)+artesunate 100 mg (adult tablet) and
mefloquine HCl 55 mg (or mef 50)+artesunate 25 mg (paediatric
tablet), (Far-Manguinhos, Brazil), given once a day for 3 days
according to body weight. This fixed dose combination has been
shown to have comparable oral bioavailability and efficacy with
the loose combination [17].
Outcome measures. Recurrent infection was defined as the
presence of asexual forms of P. falciparum parasite on a blood smear
between day-5 and 45 of follow-up (42 days+3 days to take into
account a delay in the last follow-up). Recrudescent infections
were differentiated from new infections using 3 loci genotyping as
described previously [20]. Patients with recurrent infection were
usually treated with 7 days of artesunate (2 mg/kg/day), which
was combined with 7 days of doxycycline 4 mg/kg/day (T.O.
Chemicals Ltd, Bangkok-Thailand) in patients .8 years old.
In view of the importance of the parasite reduction ratio [26],
delayed parasite clearance was considered if patients were still
parasitaemic 48 hours (day-2) after the baseline malaria positive
smear.
In vitro studies of P. falciparum drug susceptibility
Parasites isolates were obtained from patients with acute P.
falciparum malaria infection attending the research clinics. Only
primary infections were assessed. Isolates were collected if the
parasite density was at least 5 parasites/1,000 red blood cells
(RBC), from patients attending the clinic, whether enrolled in one
of the studies or not. Venous blood (5 ml) was collected into a
sterile VacutainerH tube containing 0.05 ml Potassium-EDTA.
Samples were kept at room temperature and transported within
the next 4–6 hours to the main laboratory, where they were set up
in continuous culture immediately. The minimum parasitaemic
threshold required for parasite growth in culture, as well as the
necessity to take 5 ml of blood limited the evaluation of P.
falciparum drug susceptibility to patients with higher parasitaemia
who agreed to have a venopuncture (usually adults).
In vitro drug assay. Drug susceptibility testing by
hypoxanthine uptake has been described previously by
Brockman [23]. Briefly sodium artesunate (AS), and mefloquine
Mefloquine-Artesunate Efficacy
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(MFQ) were dissolved in 70% ethanol at a concentration of 1 mg/
ml, and serial dilutions (683 ng/ml to 0.67 ng/ml for mefloquine
and 33.46 ng/ml to 0.03 ng/ml for artesunate) were made in
complete RPMI medium. The solvent in the final concentrations
had no significant effect on parasite growth when compared to
culture media. All concentrations, including drug-free controls,
were distributed in duplicate in 96-well tissue culture plates. The
drug-plates were made in bulk and stored at 280uC until use (for
up to 3 months). The reproducibility of IC50 measurements was
assessed regularly using cloned K1 isolates of P. falciparum.
Molecular analysis of pfmdr1
DNA for molecular analysis of pfmdr1 copy number was
available from whole blood (in EDTA or heparinised tubes, stored
at 270uC), or from 50 ml of capillary blood transferred to
WhatmanTM filter paper. In order to investigate changes in
resistance markers over time parasite genotypes were assessed each
year since 1996, with the exception of 1998, 2000 and 2007, using
venous blood taken before treatment from a random selection of
patients with primary P. falciparum infections. Randomisation was
stratified by age and sex to represent the population seeking care
for malaria in the outpatient’s clinics.
Pfmdr1 copy number was assessed by quantitative PCR (ABI
sequence detector 7700; Applied BiosystemsTM) using the methods
described previously [25]. All reactions were performed in
triplicate and were rejected if they did not conform to exponential
kinetics. Single nucleotide polymorphisms in pfmdr1 were detected
by nested PCR-RFLP methods as described [25]. All PCRs and
digests included as positive and negative controls DNA of
laboratory strains 3D7, HB3, 7G8 and Dd2, respectively.
Statistical Analysis
Data were analyzed using SPSS for WindowsTM (Version 14,
SPSS Inc.) and STATA (Version 10, Stata Corp.). Differences in
settings, sequence randomization, mefloquine treatment timing,
and study procedures were included in the assessment of
heterogeneity between studies using the Cochran Q test and the
I2 test [27]. The cumulative risk of failure at day-42 was calculated
by survival using the Kaplan Meier method. Indeterminate
genotyping results and new infections were censored at the date
of the reappearance of the P. falciparum parasites. PCR results were
deemed indeterminant if only one of the three gene locus was
amplified, or if analysis of genetic frequency of alleles in the
population revealed a recrudescent pair as statistically insignificant
[20]. The risks of treatment failure (PCR-adjusted) over time were
compared by the Mantel-Haenszel log rank test. In the
multivariate analysis, temporal trends in efficacy were assessed
by using a Cox regression model after controlling for known risk
factors such as age, parasitaemia at baseline, and mixed parasite
infection. Non-adjusted and adjusted Hazard ratios (HR and
AHR) and Odds ratios (OR and AOR) were also presented. A
stepwise logistic regression was used to analyze the changes in
delayed parasite clearance time, with the model including
variables significantly associated to parasite clearance time in the
univariate analysis (level of significance if p,0.10), as well as other
potential risks factors such as age, sex, admission parasitaemia,
mixed parasite infection, and type of drug regimen.
Gametocytaemia was considered as a binary variable (present/
absent) and analyzed on admission, at day-1, 2, 3, 7, and weekly
thereafter until day-42. Gametocyte carriage rates were presented
as person-gametocyte-weeks (PGW, number of weeks patients had
gametocytes/number of weeks patients were followed-up), and
expressed per 1,000 weeks of follow-up. Prevalence rate on
admission, overall carriage rate and among patients without
gametocyte on admission were calculated yearly.
In vitro dose-response curves were analyzed by fitting the data
to an inhibitory E-max pharmacokinetic model using WINNON-
LIN (Version 4.1, Pharsight Corporation) and the IC50 values, and
coefficients of variation calculated. Temporal trends for meflo-
quine and artesunate IC50 were analyzed on the ln-transformed
data.
Regression analysis on the ln-transformed values was performed
to investigate association between the IC50 and the pfmdr1 copy
number using the isolates for which both the IC50 and the copy
number were available.
Changes in pfmdr1 copy number, gametocyte carriage rates, and
the proportions of patients remaining febrile and/or parasitaemic
on day 2–4 over the years were analyzed by x2 test for trend.
Results
The efficacy of the MAS3 combination was evaluated in 3,264
patients with uncomplicated P. falciparum malaria infections,
enrolled in 9 trials, between 1995 and 2007 (Table 1).
Heterogeneity between studies was low and was not significant
(I2 test = 34%, p=0.109, Cochran Q test).
The admission characteristics of patients are presented in
Table 2. Overall 36% (1,159/3,264) of the patients enrolled were
children under 15 years. In adults, there was a preponderance of
males (73%, 1,533/2,105). Overall 19% (n=625) of patients did
not complete the 42-day follow-up period. The main reasons for
loss of follow-up were change of address and employment
obligations (592/625). The drug combination was generally well
tolerated and few patients reported having serious adverse events
[11–18]. Only one patient (0.03%; 95% CI, 0.0–0.2) deteriorated
after starting MAS3 and required parenteral treatment; three
deaths were reported (0.09%; 95% CI, 0.02–0.31). None were
related to malaria or to an adverse drug event. There were no
significant differences in age, sex and presence of mixed infections
on admission between patients lost to follow up and those who
completed it.
Clinical and parasitological responses
Changes in fever clearance times were evaluated in the 2,029
(62%) of patients who presented with fever (Table 3). Overall,
91.4% (95% CI, 90.1–92.6) of patients were afebrile by day-2, and
98.7% (95% CI, 98.0–99.1) by day-3 without significant time
trend. Mean haematocrit on admission was 37.1% (95% CI, 36.9–
37.3) and remained unchanged over the 13 year period. Mean
fractional reductions in haematocrit from baseline at day-7 did not
differ significantly by year (overall mean reduction of 7.4%; 95%
CI, 6.9–7.9).
Parasite clearance times were available for 3,218 patients
(98.6%), (Table 3). There was a significant increase in the
proportion of patients failing to clear their parasitaemia by day-2
over the study period (p,0.001, test for trend). Before 2001,
95.5% (1,256/1,315) were aparasitaemic within 48 hours com-
pared to 78.1% (1,487/1,903) between 2001 and 2007
(OR=5.96; 95% CI, 4.49–7.90, p,0.001). By day-3, 99.8%
(1,313/1,315) patients had cleared their parasitaemia before 2001,
but this fell to 95.9% (1,825/1,903) thereafter, (p,0.001),
(Figure 1). Whereas until the end of 2000, no patients (0/
1,315) were parasitaemic on day-4, between 2001 and 2007 there
were 13 patients (0.7%) with parasites seen on day-4 (p=0.007).
After accounting for age, sex, presence of a mixed (P.
falciparum+P. vivax) infection, and haematocrit on admission, the
increase in parasite clearance time over the 13 year study period
Mefloquine-Artesunate Efficacy
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remained significant (AOR=1.11; 95% CI, 1.06–1.16, p,0.001)
with a 0.05% annual increase of patients with delayed parasitae-
mia. In the same multivariate analysis, parasitaemia on admission
(AOR=2.47; 95% CI, 2.13–2.87, p,0.001), gametocytaemia on
admission (AOR=1.59; 95% CI, 1.07–2.37, p=0.023), and site of
recruitment (AOR=0.32; 95% CI, 0.23–0.45, p=0.001) were
significantly associated with failure to clear parasitaemia within
48 hours.
Gametocyte carriage
Overall 6.3% (196/3,109) of patients had patent gametocytae-
mia on admission and this proportion increased from 1.2% (6/
482) in 1995 to 7.2% (10/139) in 2007 (p=0.001, test for trend),
resulting in a significant increase in gametocyte carriage rate over
the study period (p=0.001, test for trend), (Table 4). However,
the gametocyte carriage rate among patients without gametocyte
on admission remained unchanged throughout the study period
(p=0.30, test for trend).
Patients who cleared their parasitaemia on day-1 had a lower
gametocyte carriage (10 per 1,000 person-gametocyte-week (or
PGW); 95% CI, 7–13) than those whose parasitaemia was cleared
on day-2 (15 per 1,000 PGW; 95% CI, 13–18, p=0.009), or on
day-3 or later (20 per 1,000 PGW; 95% CI, 14–26, p=0.051),
(Figure 2).
The majority of patients without gametocytaemia on admission,
who later developed gametocytaemia, did so on day-1 (43%). The
proportion of patients with gametocyte appearance during follow-
up did not increase significantly over the years (p=0.082, test for
trend), but was related to the parasite clearance time; it increased
from 2.9% (74/2,580) among patients who cleared their
parasitaemia on day-1 or on day-2 to 5.9% (26/437) among
those who cleared their parasitaemia on day-3 or later, p=0.001.
Table 1. Patients enrolled in antimalarial drug efficacy trials who received MAS3, between 1995 and 2007, on the northwestern
border of Thailand.
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Randomized Controlled Trials
Van Vugt et al. 1998 N= 305 31 274
Van Vugt et al. 2000 N= 43 29 14
Van Vugt et al. 2002 N= 534 156 280 98
Hutagalung et al. 2005 N= 245 160 85
Ashley et al. 2004&05 N= 343 127 210 6
Ashley et al. 2006 N= 500 187 313
Unpublished N= 240 17 134 89
Sub-total N=2210 31 274 29 170 280 98 160 212 210 193 330 134 89
Open trials for routine monitoring of MAS3
Price et al. 1997 N= 453 451 2
Unpublished N= 601 246 42 145 70 49 49
Sub-total N=1054 451 2 0 0 0 0 246 0 42 145 70 49 49
Total N=3264 482 276 29 170 280 98 406 212 252 338 400 183 138
doi:10.1371/journal.pone.0004551.t001
Table 2. Demographic characteristics on admission of patients enrolled in antimalarial drug efficacy trials who received MAS3,
between 1995 and 2007.
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 Total
No enrolled 482 276 29 170 280 98 406 212 252 338 400 183 138 3264
No of males (%) 291
(60%)
190
(69%)
26
(90%)
126
(74%)
183
(65%)
67
(68%)
258
(64%)
142
(67%)
153
(61%)
215
(64%)
283
(71%)
145
(79%)
121
(88%)
2200
(67%)
Age (years)
,15 years 317
(65.8%)
92
(33.3%)
6
(20.7%)
50
(29.4%)
88
(31.4%)
38
(38.8%)
158
(38.9%)
80
(37.7%)
95
(37.7%)
107
(31.7%)
115
(28.8%)
9
(4.9%)
4
(2.9%)
1159
(35.5%)
$15 years 165
(34.2%)
184
(66.7%)
23
(79.3%)
120
(70.6%)
192
(68.6%)
60
(61.2%)
248
(61.1%)
132
(62.3%)
157
(62.3%)
231
(68.3%)
285
(71.2%)
174
(95.1%)
134
(97.1%)
2105
(64.5%)
No with mixed infections
(%)
86
(17.8%)
13
(4.7%)
1
(3.4%)
6
(3.5%)
20
(7.1%)
4
(4.1%)
36
(8.9%)
20
(9.4%)
23
(9.1%)
19
(5.6%)
30
(7.5%)
13
(7.1%)
2
(1.4%)
273
(8.4%)
Geometric mean
parasitaemia (per ml)
6745 4932 7798 5984 3776 3228 7161 10544 10765 8375 7907 9226 7674 6982
Min 16 13 631 20 6 20 13 16 79 50 32 158 158 6
Max 199526 251189 125893 251189 501187 158489 199526 199526 199526 316228 316228 199526 158489 501187
doi:10.1371/journal.pone.0004551.t002
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In the multivariate analysis, after controlling for gametocytae-
mia on admission (AOR=1.65; 95% CI, 1.09–2.49, p=0.018),
parasitaemia on admission (AOR=2.32; 95% CI, 2.00–2.69,
p=0.001), year of recruitment (AOR=1.16; 95% CI, 1.11–1.22,
p=0.001), and site of recruitment (AOR=0.37; 95% CI, 0.26–
0.51, p=0.001), patients who had a delayed parasite clearance (3
days or longer) remained at a higher risk of developing
gametocytaemia (AOR=2.29; 95% CI, 2.00–2.69, p=0.002).
Parasitological efficacy
Of the 333 recurrent infections with P. falciparum during the 42-
day follow-up period, 177 (53%) were new infections, 108 (32%)
were recrudescent infections, and in 48 (15%) cases the PCR result
was inconclusive (n=15) or samples were not available (n=33).
The median time to recrudescence occurred at 21 days of follow-
up (range 7–42 days); although time to recrudescence has
increased by one week since 2006, it has not changed significantly
Table 3. Fever and parasite clearance time (in days).
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 Total
Fever clearance
Febrile (N, %)
Day 0 (admission) 406
(100)
169
(100)
20
(100)
104
(100)
170
(100)
44
(100)
301
(100)
118
(100)
87
(100)
179
(100)
256
(100)
131
(100)
44
(100)
2029
(100)
Day 1 199
(49.0)
68
(40.2)
7
(35.0)
35
(33.7)
65
(38.2)
14
(31.8)
141
(46.8)
29
(24.6)
18
(20.7)
55
(30.7)
90
(35.2)
64
(48.9)
18
(40.9)
803
(39.6)
Day 2 43 (10.6) 22 (13.0) 5 (25.0) 4 (3.8) 9 (5.3) 2 (4.5) 25 (8.3) 4 (3.4) 3 (3.4) 19 (10.6) 22 (8.6) 13 (9.9) 3 (6.8) 174 (8.6)
Day 3 5 (1.2) 6 (3.6) 2 (10.0) 1 (1.0) 1 (0.6) 0 1 (0.3) 0 1 (1.1) 5 (2.8) 4 (1.6) 0 1 (2.3) 27 (1.3)
Day 4 2 (0.5) 0 0 0 0 0 0 0 0 2 (1.1) 1 (0.4) 0 0 5 (0.2)
Day 5 1 (0.2) 0 0 0 0 0 0 0 0 0 1 (0.4) 0 0 2 (0.1)
Parasite clearance
Smear positive (N, %)
Day 0 (admission) 468
(100)
273
(100)
29
(100)
168
(100)
279
(100)
98
(100)
402
(100)
211
(100)
252
(100)
337
(100)
393
(100)
182
(100)
126
(100)
3218
(100)
Day 1 189
(40.4)
106
(38.8)
20
(69.0)
96
(57.1)
150
(53.8)
53
(54.1)
274
(68.2)
159
(75.4)
201
(79.8)
276
(81.9)
320
(81.4)
122
(67.0)
91
(72.2)
2057
(63.9)
Day 2 17 (3.6) 9 (3.3) 2 (6.9) 10 (6.0) 16 (5.7) 5 (5.1) 47 (11.7) 46 (21.8) 42 (16.7) 108 (32.0) 118 (30.0) 31 (17.0) 25 (20.0) 476 (14.8)
Day 3 0 0 0 1 (0.6) 1 (0.4) 0 8 (2.0) 8 (3.8) 13 (5.2) 19 (5.6) 26 (6.6) 3 (1.6) 1 (0.8) 80 (2.5)
Day 4 0 0 0 0 0 0 2 (0.5) 1 (0.5) 1 (0.4) 7 (2.1) 1 (0.3) 1 (0.6) 0 13 (0.4)
Day 5 0 0 0 0 0 0 0 0 0 1 (0.3) 1 (0.3) 0 0 2 (0.1)
doi:10.1371/journal.pone.0004551.t003
Figure 1. Percentage of patients who had cleared parasitaemia at Day-2 and Day-3 1995–2007.
doi:10.1371/journal.pone.0004551.g001
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over the 13 year period, and neither has the time to re-infection
(Table 5).
Parasitological efficacy (non PCR-adjusted) increased signifi-
cantly over time as the risk of P. falciparum parasites recurrence
within 42 days of follow-up, after controlling for age, sex, mixed
parasite infections, gametocyte and parasitaemia on admission,
decreased (AHR=0.88; 95% CI, 0.86–0.91, p=0.001).
A small but statistically significant decline in PCR-adjusted
parasitological efficacy (assessed at day-42) was observed over the
study period (HR=1.13; 95% CI, 1.07–1.19, p,0.001). However
the efficacy of MAS3 in 2007 remained above 95%: 96.5% (95%
CI, 91.0–98.7), (Figure 3). The temporal trend of a slight decline
in MAS3 efficacy remained after controlling for age, sex, baseline
parasitaemia and gametocytaemia, mixed infections and the
patients’ enrolment location (AHR=1.11; 95% CI, 1.02–1.21,
p=0.020).
In vitro drug sensitivity
In total, 1,581 P. falciparum isolates were assayed for in vitro
drug susceptibility during the study period; artesunate IC50 could
be determined satisfactorily in 1,179 (75%) isolates and
mefloquine IC50 in 1,195 (76%). Between 1995 and 2001 there
was a significant decrease in the IC50s of both artesunate (13%
per year, p,0.001) and mefloquine (9.1% per year, p,0.001).
From 2002 this trend reversed for artesunate with IC50s
increasing 41% per year (p,0.001) until 2006, although
decreasing in 2007 (Figure 4a). Mefloquine IC50s also rose
between 2001 and 2004, but fell again in 2006–7 (Figure 4b).
Between 1995 and 2007, the geometric mean mefloquine IC50
fell from 95.5 nM/l (95% CI, 70.4–129.7) to 37.1 nM/l (95% CI,
26.5–52.3, p,0.001), and the IC50 of artesunate from 6.47 nM/l
(95% CI, 5.34–7.86) to 4.19 nM/l (95% CI, 3.20–5.46,
p=0.009).
Table 4. Gametocyte prevalence rate on admission and gametocyte carriage rate (overall and among patients without
gametocytaemia on admission).
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Gametocytaemia on admission
Total number of patients 482 276 29 168 279 98 400 212 252 337 400 176 139
Prevalence (%) 1% 6% 7% 11% 8% 7% 3% 6% 5% 9% 10% 11% 7%
Overall gametocyte carriage rate
Person-weeks of follow-up 1658 1052 143 641 988 382 2036 1148 1326 1817 2086 919 722
Gametocyte carriage (in weeks) 9 10 0.6 19 15 10 14 12 13 33 42 21 11
Gametocyte carriage rate (per 1000 PGW) 5 10 4 29 15 27 7 10 10 18 20 23 15
Patients without gametocyte on admission
Person-weeks of follow-up 1569 939 127 554 888 336 1912 1048 1223 1419 1846 803 650
Gametocyte carriage (in weeks) 6 1 0 2 2 1 6 2 3 6 6 6 2
Gametocyte carriage rate (per 1000 PGW) 4 1 0 4 3 3 3 2 2 5 3 7 3
doi:10.1371/journal.pone.0004551.t004
Figure 2. Relationship between parasite clearance time and gametocyte carriage. Gametocyte carriage rate is expressed per 1,000 person-
gametocyte-week (PGW).
doi:10.1371/journal.pone.0004551.g002
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Pfmdr1 copy number
A total of 531 isolates were selected randomly for genetic
analysis with pfmdr1 copy number successfully determined in 84%
(444/531) of these isolates. The proportion of infections with two
or more pfmdr1 copy number rose from 30% (12/40) in 1996 to
53% (24/45) in 2006 (p=0.012, test for trend), (Table 6 and
Figure 5).
Among 408 patients treated withMAS3 regimen for whom in vivo
and molecular data were available, 183 (45%) were infected with
parasites with increased pfmdr1 copy number. Infections with
increased pfmdr1 copy number were at greater risk of recrudescence
by day-42 compared to single copy number infections (AHR=10.0;
95% CI, 3.0–33.3, p,0.001). There was no difference in the
proportion of patients parasitaemic on day-2 in those with single
(25%, 46/188) or increased pfmdr1 copy number (22%, 34/155,
p=0.61), even after controlling for baseline parasitaemia.
In the 394 isolates with in vitro and molecular data,
amplification of pfmdr1 was associated with a 2.9 fold increase in
mefloquine IC50 (geometric mean= 42.2 nM/l; 95% CI, 37.9–
46.8 to 120.8 nM/l; 95% CI, 107.0–136.2, p,0.001) and a 1.7
fold increase in artesunate IC50 (1.99 nM/l; 95% CI, 1.81–2.19 to
3.33 nM/l; 95% CI, 2.94–3.80, p,0.001). The rise in IC50
associated with increased pfmdr1 copy number was greater during
the period 1996–2001 compared to thereafter for both artesunate
(Pre: 2.1 vs. Post: 1.4 fold, p=0.007) and mefloquine (Pre: 3.5 vs.
Post: 2.6 fold; p=0.076). In contrast there was no change in the
risk of treatment failure associated with increased copy number
over the study period.
Table 5. PCR-confirmed novel and recrudescent infections and time to recrudescence.
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 Total
Total patients treated
with MAS3
482 276 29 170 280 98 406 212 252 338 400 183 138 3264
Inconclusive (N) 0 0 0 0 1 1 4 0 0 2 4 3 0 15
Missing (N) 11 3 0 0 0 2 3 0 1 9 2 0 2 33
Novel infections (N) 11 5 0 1 7 13 29 12 13 23 30 25 8 177
Days to novel infection
median, [range]
35
[21–64]
42
[35–63]
- 37 36
[28–42]
36.5
[20–49]
34.5
[14–63]
42
[21–63]
43.5
[14–63]
34
[13–61]
43
[14–70]
33
[21–63]
31.5
[14–50]
34.0
[13–45]
Recrudescent infections
(N)
8 5 0 0 1 7 14 8 9 20 25 7 4 108
Days to recrudescence
median, [range]
21
[14–41]
21
[16–36]
- - 21 23
[15–33]
21
[14–42]
23.5
[21–42]
21
[7–28]
21
[15–42]
23
[14–42]
28
[21–42]
28
[23–34]
21
[7–42]
doi:10.1371/journal.pone.0004551.t005
Figure 3. PCR-adjusted parasitological efficacy (95% CI) at Day-42 following MAS3 treatment. Parasitological efficacy (PCR-adjusted) of
the mefloquine-artesunate 3-day combination therapy was evaluated at Day-42 of follow-up between 1995 and 2007. Efficacy is given as a
percentage (95% CI).
doi:10.1371/journal.pone.0004551.g003
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Discussion
The rapid development of mefloquine resistance in Tak
province on the Thai-Myanmar border in the early 1990s led
to the introduction of the three day combination of artesunate
and mefloquine (MAS3) as first line treatment for uncomplicated
P. falciparum malaria in 1994 in the camps for displaced persons.
Despite the prevailing high levels of mefloquine resistance, cure
rates increased to more than 90% and MAS3 had a spectacular
impact on the incidence of P. falciparum malaria cases in the
camps [19]. In vitro susceptibility of P. falciparum isolates to
mefloquine improved significantly until 1999, attributed to the
eradication of the more mefloquine resistant ‘‘strains’’ and the
return of more mefloquine-sensitive ‘‘wild-type’’ parasites [23].
This was explained by the considerably reduced transmission
advantage of mefloquine-resistant parasites when treated by
MAS3, which are less fit than their mefloquine-sensitive
counterparts [28], and consequent repopulation by ‘‘wild type’’
Figure 4. Drug sensitivity of P. falciparum isolates for artesunate (Figure 4a) and mefloquine (Figure 4b). Isolates from primary infections
were collected at SMRU clinics between 1995 and 2007 and assayed for sensitivity to artesunate and mefloquine, IC50 geometric means are given as
nM/l with [95% CI].
doi:10.1371/journal.pone.0004551.g004
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parasites from Myanmar (which there is little or no drug pressure)
[26].
Over the subsequent 13 years of continuous MAS3 deployment
the cure rates assessed at day-42 remain well above 90%. However
despite this unprecedented level of sustained efficacy over the 13
year period and a significant decline in the prevalence of
falciparum malaria on the Thai side of the border, there are
some worrying trends. The in vitro susceptibility of P. falciparum
isolates to artesunate has now returned to the levels observed in
1995, although the magnitude of this change is small (+/24 nM)
and within the accepted drug sensitivity levels. Mefloquine
susceptibility has fluctuated widely, and its association with the
pfmdr1 copy number seems to have changed over the years. These
changes in antimalarial activity in vitro have not been associated
with a sharp reduction in cure rates, as happened when
mefloquine was used as monotherapy [7,19]. The changes in
artesunate susceptibility could be related to the increases in pfmdr1
copy number [25] although the patterns are dissimilar, and not
well correlated with changes in mefloquine susceptibility. Over the
last 4 years, there has been no further increase in the proportion of
isolates with increased pfmdr1 copy number, and yet there are
indications that artemisinin efficacy has declined as evidenced by
an increase in the parasite clearance time. The decrease in in vitro
susceptibility to artesunate after 2002 could not be explained by
mechanisms associated with mefloquine resistance (predominantly
pfmdr1 amplification). The correlation between artesunate and
mefloquine IC50s evident before 2002 was no longer evident
afterwards. This suggests the emergence of a new factor affecting
artesunate susceptibility, which could include either novel
mutations within the pfmdr1 gene, increased gene expression or
alternate genetic events.
The changes in the early in vivo parasitological responses to
MAS3 are more concerning. Rapid parasite clearance is the
pharmacodynamic hallmark of artemisinin and its derivatives.
This is associated with reduced gametocyte carriage compared
with other antimalarial drugs. There has been a small but
significant slowing of parasite clearance, reflected by the increasing
proportion of patients with parasitaemia persisting on the second
and subsequent days following the start of treatment. Up until
2001 less than 7% of patients were parasitaemic on the second day
of follow-up; however this figure has more than doubled in recent
years. The delay in parasite clearance has been associated with a
small increase in treatment failure rates, presumably reflecting a
slight reduction in initial parasite reduction ratios, which results in
a greater number of parasites for mefloquine to remove in the
third and subsequent post treatment replication cycles [9]. Slowing
of parasite clearance was associated with increased gametocyte
carriage, and therefore presumably increased transmissibility of
Figure 5. Proportion of primary infections with increased Pfmdr1 ($2) copy number. Isolates from primary infections were used for genetic
analysis between 1996 and 2006. Increase in isolates with 2 or more copy number is given in percentage of the total.
doi:10.1371/journal.pone.0004551.g005
Table 6. Pfmdr1 copy number in parasite isolates collected in patients with primary uncomplicated P. falciparum infection.
1996 1997 1999 2001 2002 2003 2004 2005 2006
Total isolates collected 50 53 60 68 76 46 61 67 50
Isolates with determination of pfmdr1 copy number 40 49 47 57 70 36 45 55 45
Pfmdr1 copy number:
- 1 28 (70%) 29 (59%) 27 (58%) 37 (65%) 52 (74%) 24 (66%) 18 (40%) 27 (49%) 21 (47%)
- 2 8 (20%) 7 (14%) 11 (23%) 10 (18%) 12 (17%) 6 (17%) 13 (29%) 16 (29%) 11 (24%)
- $3 4 (10%) 13 (27%) 9 (19%) 10 (17%) 6 (9%) 6 (17%) 14 (31%) 12 (22%) 13 (29%)
doi:10.1371/journal.pone.0004551.t006
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the more drug tolerant phenotype. This is an important public
health point as the marked effect of artemisinin derivatives in
reducing gametocyte carriage is an important contributor to their
beneficial effects in malaria transmission control. Increased rates of
gametocyte carriage were a harbinger of sulfadoxine-pyrimeth-
amine resistance in Southern Africa, before any discernable effect
on cure rates [29]. The dissociation between in vitro and in vivo
observations suggests that the conventional in vitro approach to
susceptibility testing may not be appropriate for evaluating
artesunate tolerance. These are very early signs detectable only
in this site, with the largest and most detailed longitudinal
experience of antimalarial drug responses in the world. Several
different factors affect cure rates. Young age of the patients, pure
P. falciparum infections rather than infections mixed with P. vivax on
admission, a parasitaemia over 40,000 parasites per ml on
admission and site have been found to be independent risk factors
for treatment failure following MAS3 [18]. However the temporal
trends remain significant even after controlling for all these factors.
The efficacy of the 3-day MAS regimen falls when the level of
mefloquine resistance increases such that drug levels remaining
after artesunate has been eliminated are not sufficient to eliminate
completely the residual parasites. Mefloquine resistance arises
readily as a result of gene amplification [25]. Drug pressure, and
therefore the risk of selecting mefloquine resistant parasites results
from increasing drug use, inadequate regimens, and from
unprotected monotherapy [30]. Mefloquine has been used scantily
within Myanmar. The 2-day regimen that was used by the Thai
national programme was instituted in the early years of the
combination therapy, based on non-PCR adjusted cure rates at 28
days of follow-up [31] and on the assumption that adherence to a
two day regimen would be better than that with a three day
regimen [3]. However with a two-day regimen, blood levels of
artesunate cover one parasite asexual cycle only, so residual
numbers of parasites left for the mefloquine component to remove
are up to four orders of magnitude higher than with the three day
regimen. This would be expected to increase the selection pressure
for the emergence and spread of mefloquine resistant strains [32].
Drug pressure may have been further aggravated by the lower
mefloquine dosage (15 mg/kg) used in monotherapy in 62 out of
the 76 Thai provinces until recently [6]. However the inconsistent
trend in the in vitro susceptibility assessments of mefloquine and
the lack of any shortening in the interval to recrudescence argues
against a major decline in mefloquine susceptibility.
Despite some worrying signs, which could only have been
detected by these very large prospective studies, the 3-day
mefloquine-artesunate combination is still more than 95%
effective in Tak province, 13 years after its introduction in the
camps for displaced persons. Considering that resistance to
mefloquine monotherapy had reached very high levels before this
combination was deployed, and that surrounding areas deployed
different dose regimens, its longevity is remarkable. Our data
suggest that changes have occurred in the prevalent P. falciparum
population resulting in small but significant increases in parasite
tolerance to the artesunate component of MAS3. These are
considerably less in magnitude than those reported recently from
Western Cambodia [33] but they may be the harbinger of much
higher levels of artemisinin tolerance. Although pfmdr1 amplifica-
tion is a contributor to artemisinin susceptibility, the main cause of
this reduction in artesunate susceptibility is not known. Of
particular concern is the increased transmissibility of these tolerant
parasites. The changes are small, but they justify a very close
monitoring of the susceptibility of P. falciparum in this area, and in
particular vigilance to detect early emergence of higher levels of
artemisinin resistance. The development of resistance to artemi-
sinin and its derivatives would be a global disaster for malaria
control as current treatment regimen are dependant on this class
of antimalarial drugs.
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